In the BioHarmony Drug Report Database

"Preview" Icon

Bazedoxifene

Duavee, Conbriza (bazedoxifene) is a small molecule pharmaceutical. Bazedoxifene was first approved as Duavee on 2009-04-17. It is used to treat menopause in the USA. It has been approved in Europe to treat postmenopausal osteoporosis. The pharmaceutical is active against estrogen receptor beta and estrogen receptor. Duavee’s patent is valid until 2027-03-10 (FDA).

 

Trade Name

 

Conbriza
 

Common Name

 

bazedoxifene
 

ChEMBL ID

 

CHEMBL46740
 

Indication

 

menopause, postmenopausal osteoporosis
 

Drug Class

 

Antiestrogens of the clomifene and tamoxifen groups

Image (chem structure or protein)

Bazedoxifene structure rendering